Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Metamizole · 1 trial · 2 indications
The primary outcome will help to determine whether adding metamizole (dipyrone) or ibuprofen to opioids is more effective than adding placebo in reducing average daily pain intensity (primary outcome) in cancer patients. \- Average of 5-day average daily patient reported pain assessed on days 3 to 7 by numeric rating scale (NRS); The NRS ranges from 0 ("no pain") to 10 ("pain as bad as the patient can imagine")
| Arm | Type | Description |
|---|---|---|
| Opioid + Metamizole | EXPERIMENTAL | - |
| Opioid + Ibuprofen | EXPERIMENTAL | - |
| Opioid + Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Metamizole | DRUG | Metamizole 4 g/d as: 2 capsules of 500 mg Metamizole each (1000 mg) taken 4 x daily orally. |
| Ibuprofen | DRUG | Ibuprofen 1.2 g/d as: 2 capsules of 150 mg Ibuprofen each (300 mg) taken 4 x daily orally |
| Placebo | OTHER | Placebo 0 g/d as: 2 capsules containing inactive substance (mannitol) taken 4 x daily orally. |
Inclusion Criteria: * Inpatient setting (discharge possible, if patient returns for End of Study Visit) * Diagnosis of metastatic or locally advanced cancer * Cancer pain as defined by IASP (International Association for the Study of Pain) * Cancer pain therapy with opioids indicated for pain manag...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Masimo Corporation | MASI | 2 | PHASE1 | Diprivan, Astra-Zeneca |
| Telix Pharmaceuticals Limited Sponsored ADR | TLX | 1 | PHASE1 | 153Sm-DOTMP |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE1 | of humanized nerve growth factor antibody |